Pancreatic Cancer Treatment Market By Treatment Type (Surgery {Whipple Procedure, Distal Pancreatectomy, Total Pancreatectomy}, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, Palliative Care, Others), By Drug Type (Approved Drugs {Gemcitabine, Nab-Paclitaxel, Erlotinib, Liposomal Irinotecan}, Pipeline Drugs {Oncolytic Viruses, Epigenetic Modulators}), By Cancer Type (Exocrine Pancreatic Cancer, Pancreatic Neuroendocrine Tumors, Others), By Route of Administration (Oral, Injectable {Intravenous, Intraperitoneal}), and By End-User (Hospitals, Ambulatory Surgical Centers, Cancer Research Institutes, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Pancreatic Cancer Treatment market accounted for USD 4.34 Billion in 2024 and is expected to reach USD 18.7 Billion by 2035, growing at a CAGR of around 14.2% between 2025 and 2035. The pancreatic cancer treatment market primarily focuses on solutions for the diagnosis and treatment of pancreatic cancer, which is particularly lethal and is often diagnosed at a later stage. It comprises over-the-counter medications like surgery, chemotherapeutic agents, radiation therapy, target therapy, immunotherapy, and end-of-life care.

The market growth is stimulated by the growing frequency of pancreatic cancer and improvements in drugs and treatment regimens, including the development of personalized therapy. Despite constraints such as high treatment costs, the market is expanding due to increased research and the development of new treatment methods, including innovative therapies and improved patient management approaches. Major stakeholders vary in the global radiation therapy market, including pharmaceutical manufacturers, hospitals and clinics, and research centers aimed at enhancing treatment effectiveness.

Report Scope:

Market Dynamics

Rising Global Incidence of Pancreatic Cancer Fuels Demand for Advanced Treatment Solutions

Pancreatic cancer incidence around the globe is growing, and that remains the driving factor of the pancreatic cancer treatment market. This points the way to a continually rising number of cases diagnosed with the disease, coupled with an increased need for therapeutics to enhance the quality of life for patients.

Pancreatic cancer is often detected at more advanced stages because the disease is not easily noticeable in its early stages. This trend has made there a need for improvement of the therapy, which includes chemotherapy, immunotherapy, and those treated therapies. An estimated 64,050 people in the USA were diagnosed with pancreatic cancer in 2023, making it the third leading cause of cancer-related deaths. The rise in cases creates a greater need for innovative treatment methods, which would significantly boost the global market.

Government Funding and Initiatives Accelerate Pancreatic Cancer Research and Treatment Development

There are no other sources of funding for diagnosis and treatment of pancreatic cancer other than through government grants. Since pancreatic cancer is one of the deadliest and most aggressive forms of cancer, many researchers, practitioners, and healthcare organizations are interested in improving new treatment strategies and techniques for early diagnostics. Currently, governments and established learning institutions are earmarking more funds for research, trials, and the development of new treatments. For example, the United States National Institutes of Health (NIH) National Cancer Institute planned to spend about 192 million US dollars in 2022 for research on pancreatic cancer.

Such approaches include the development of targeted therapy, immunotherapy, and personalized medicine, all aimed at improving survival rates and enhancing therapeutic practices. Such investments are crucial to overcoming the obstacles to treating pancreatic cancer, which has fueled the expansion and development of the market.

Adverse Side Effects of Aggressive Treatments Hinder Patient Compliance and Quality of Life in Pancreatic Cancer

The side effects of more intensive therapeutic approaches serve as a constraint in the pancreatic cancer treatment market, as they can lead to poor patient adherence and a reduced quality of life. Chemotherapy, targeted therapy, and immunotherapy that are used to treat pancreatic cancer have negative effects like vomiting, general body weakness, hair loss, and infected immune systems. These side effects are unpleasant and may be severe enough to cause patients to stop taking their medications or follow through with regimens as prescribed.

Further, such treatments can be very tiring to the body and emotionally draining. Thus, they may lower the quality of life for the patients. Since PC is often diagnosed at a later stage, the association of aggressive therapy and low therapeutic index makes management of these patients difficult for clinicians and a concern for patients. This concern undermines existing treatment regimens and highlights the need for better-tolerated options, posing a market expansion threat.

Emerging Targeted Therapies Offer Promising Opportunities for More Effective Pancreatic Cancer Treatments

The market for pancreatic cancer treatment holds significant growth potential for new biomarker-targeted therapies. The idea of these therapies is to hit molecular targets that are unique to pancreatic cancer cells and thus, the therapies are less billed to normal cells than traditional chemotherapy radiation. Scientists formulate molecular therapies to increase specificity on target cells and decrease harm to other cancer cells to give patients better survival rates and quality of life.

Due to the recent development of molecular markers that indicate the genetic types of pancreatic cancer, knowledge of the genetic and molecular basis of this disease has improved, allowing for the creation of new targeted drugs. Current clinical trials show promising data indicating that drugs like PALOMA-3 and Larotrectinib may enhance treatment effectiveness. These therapies are expected to become standard and complementary in treatment protocols, providing new hope to patients and driving market growth.

Strategic Partnerships and Collaborations Accelerate the Development of Innovative Pancreatic Cancer Therapies

In terms of market dynamics, alliances and partnerships are proving to be crucial for driving growth in the pancreatic cancer treatment market. When companies work hand in hand with pharmaceutical firms, academic institutions, and research organizations, they are in a better position to achieve treatment solutions collectively and at equal intervals through the synergy of skills, compounds, and technologies. These partnerships support the creation of new drugs at a faster rate against diseases, enhance the form and strategy of clinical trials, and enhance the rates of the reimbursement processes.

Cooperation between biotech companies and universities has led to the development of immunotherapy and targeted therapies for pancreatic cancer. Some of them, such as the co-partnership between Amgen and Immunocore, are pioneering and are helping to advance the system and bring potential treatments onto the horizon. Several strategic partnerships not only advance the pipeline of innovative products and services, whether through independent companies or affiliates, but also enhance global access to these treatments, indicating significant growth potential for the market.

Industry Experts Opinion

“Oncolytics is pleased to announce receipt of regulatory clearance to initiate the mFOLFIRINOX cohort in patients with newly diagnosed metastatic PDAC. We appreciate the opportunity to collaborate with PanCAN, Roche, and AIO on this cohort, which is expected to initiate enrollment in the second quarter.”

• Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics

"The Therapeutic Accelerator Award program has been an important part of PanCAN's approach to advancing innovative treatments for pancreatic cancer. We incorporated input from leading scientists and clinicians in the field of pancreatic cancer to select Oncolytics as a recipient of this award."

• Anna Berkenblit, MD, MMSc, Chief Scientific and Medical Officer at PanCAN

Segment Analysis

Based on the treatment type, the pancreatic cancer treatment market has been classified into Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, Palliative care, and Others. Chemotherapy has become the most widely used treatment option in the pancreatic cancer treatment market. Researchers have used it for several years in the treatment of pancreatic cancer due to its ability to target rapidly dividing cancer cells.

Some of the familiar chemotherapies that are often used in pairs with Gemcitabine include Nab-Paclitaxel, which is usually prescribed to patients in the advanced stages of the disease. Chemotherapy remains the sole exclusive treatment because for many patients, surgery or radiation therapy is out of the question. Even though it is rare, it remains famous due to its higher efficiency in increasing the time to live, which new treatments like immunotherapy, targeted therapy, and radiation do not afford, or at least it has not been seen yet. He said that chemotherapy is still used by oncologists all over the world because there is no other alternative treatment that could be as effective as this procedure.

Based on the drug type, the pancreatic cancer treatment market has been classified into Approved Drugs and Pipeline Drugs. The most developed segment in the pancreatic cancer treatment market is the approved drugs segment, and Gemcitabine and Nab-Paclitaxel are the leading treatments. Gemcitabine has been utilized for many years as a first-line agent in pancreatic cancer, and its use has been shown to extend survival.

Nab-Paclitaxel, in combination with Gemcitabine, has been proven very effective in the therapy of advanced pancreatic cancer. Thus, the combination is widely used. They have a long clinical history and are recognized today as foundational drugs for treating pancreatic cancer due to their effectiveness in providing therapeutic value. Despite ongoing research on pipeline drugs like oncolytic viruses and epigenetic modulators, approved drugs remain the most prevalent type due to their efficacy, regulatory approval, and widespread use in clinical practice.

Regional Analysis

The largest share of the pancreatic cancer treatment market is in North America due to the high level of development of the healthcare system, high levels of awareness, and investments in research and development. The United States occupies the leading position in the market due to its robust pharmaceutical industry, a high number of clinical trials, and the latest therapeutic advancements. Many major pharmaceutical companies worldwide are developing new drugs and therapies for pancreatic cancer, with several located in the region. These are Eli Lilly, Amgen, Merck, and many others.

Furthermore, the government continues to support research and development of new technologies through funding from the National Cancer Institute (NCI). The increase in the number of cases of pancreatic cancer especially spread out in North America, and the increased awareness of the disease, as well as the first stage, improve the need to seek treatment. The region is currently in a phase of rapid early adoption of new pancreatic cancer treatment therapies, including immunotherapy, targeted therapy, and precision medicine, despite facing existing challenges.  

The pancreatic cancer treatment market in the Asia Pacific region is growing at the highest rate due to the growing incidence of pancreatic cancer, advanced healthcare facilities, and rising awareness of the disease. Now the populations of China, India, Japan, and other countries have increased the number of cancer cases hence the need for better treatments. Increased prevalence of diagnostic methods, new-generation targeted therapies, and chemotherapy are driving market growth.

The market is expanding due to significant investments from global pharmaceutical companies like Eli Lilly & Co. and Amgen in developing and distributing pancreatic cancer treatments in this region. Efforts to obtain funds from international research organizations and other players in the healthcare field are also spearheading the development of innovative treatments through partnerships with local healthcare providers. Rising healthcare costs in the region, combined with government efforts to enhance cancer treatment are expected to increase the availability of advanced pancreatic cancer therapies and drive market growth in the APAC region.

Competitive Landscape

The players currently involved in the pancreatic cancer treatment market are Celgene Corporation, Eli Lilly, Merck & Co., Genentech, Amgen Inc., and Ipsen Pharma, among others, and constitute the most active companies in the development of new products and services in response to pancreatic cancer treatment. These companies point to therapies as future market growth drivers, including target therapies, immunotherapies, and new chemical therapies.

New topics include new molecular entities such as Eli Lilly Company, which recently received FDA approval to use Verzenio as a combination therapy for pancreatic cancer treatment, and Merck, which has made breakthroughs with Keytruda (pembrolizumab) immunotherapy. Furthermore, clinical trials and partnerships are advancing the discovery of new drugs and pipeline therapies, exciting companies like OncoOne Therapeutics and Exelixis. It also shows the rising trend of partnership between pharma industries and academic research centers to meet the growing demand for better treatment of pancreatic cancer.

Pancreatic Cancer Treatment Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In March 2023, Novartis entered Phase I of clinical development for LGK-974 as a treatment for metastatic pancreatic cancer. According to Global Data, the Phase Transition Success Rate (PTSR) for advancing from Phase I to Phase II for drugs targeting metastatic pancreatic cancer is 88%.
• In December 2022, scientists introduced the world’s first early screening test for pancreatic cancer, which uses worms to detect tumors. Launched in Japan this month, the test claims to be 100% accurate in identifying cancer and can detect it in its early stages.

Report Coverage:

By Treatment Type

• Surgery
  • Whipple Procedure
  • Distal Pancreatectomy
  • Total Pancreatectomy   
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
•  Immunotherapy
• Palliative Care
•  Others

By Drug Type

Approved Drugs

• Gemcitabine
• Nab-Paclitaxel
• Erlotinib
• Liposomal Irinotecan
• Pipeline Drugs
  • Oncolytic Viruses
  • Epigenetic Modulators

By Cancer Type

• Exocrine Pancreatic Cancer
• Pancreatic Neuroendocrine Tumors
• Others

By Route of Administration

• Oral
• Injectable
  • Intravenous
  • Intraperitoneal

By End-User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Cancer Research Institutes
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Celgene Corporation
• Eli Lilly and Co.
• Amgen Inc.
• Merck & Co.
• Genentech
• Novartis International AG
• AbbVie Inc.
• Bayer AG
• Sanofi
• Ipsen Pharma
• Bristol-Myers Squibb
• OncoOne
• Exelixis, Inc.
• Karyopharm Therapeutics
• Clovis Oncology

Frequently Asked Questions (FAQs)